Teva Unit Marketed Opioid For Off-Label Uses, Judge Hears
Teva unit Cephalon saw sales of its opioid lollipop Actiq soar after it began marketing the product for non-FDA approved off-label uses, a judge heard Tuesday in recorded testimony from ex-Cephalon...To view the full article, register now.
Already a subscriber? Click here to view full article